Jonathan Barratt

University of Leicester — United Kingdom

Medicine · Health Sciences

75h-index23.1kcitations659works7.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Diseases and Glomerulopathies(368), Platelet Disorders and Treatments(104), Chronic Kidney Disease and Diabetes(90), Autoimmune Bullous Skin Diseases(71), Complement system in diseases(58)

Publications640 total

A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop
Kidney International Reports·2025Open Access
Disease modification in immunoglobulin A nephropathy
Nephrology Dialysis Transplantation·2025Open Access
Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation
Kidney International Reports·2025Open Access
Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon
Clinical Kidney Journal·2025Open Access
Corrigendum to “Treatment of patients with IgA nephropathy: a call for a new paradigm.” Kidney International 2025;107:640–651
Kidney International·2025Open Access
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
New England Journal of Medicine·2025· 9 cited
Iptacopan in Patients With IgA Nephropathy From East Asia
Kidney International Reports·2025Open Access
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
New England Journal of Medicine·2025· 11 cited
BEYOND THE ESOPHAGUS: DUPILUMAB-INDUCED REMISSION IN NON-ESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISEASE
Annals of Allergy Asthma & Immunology·2025Open Access
Genetic Evaluation of the Role of Galactose-Deficient IgA1 in IgA Nephropathy: Evidence from Association Testing and Mendelian Randomization
2025Open Access
Is It Time to Consider Population-Based Urine Dipstick Screening for Early Detection of Kidney Disease?
Kidney International Reports·2025Open Access
How should we approach the treatment of IgAN in 2025?
Nephrology Dialysis Transplantation·2025Open Access
DMX-200 in Patients With Primary Focal Segmental Glomerulosclerosis: Results of the Phase 2 ACTION2 Trial
Kidney International Reports·2025· 1 citedOpen Access
Individualized treatment effects of corticosteroids in IgA nephropathy
2025Open Access
B Cell-Specific Deletion of C1GALT1 Elevates Serum Gd-IgA1 but Fails to Induce Mesangial IgA Deposition in Humanized IGHA1 Mice
Journal of the American Society of Nephrology·2025
Efficacy of Ravulizumab on Proteinuria Response by Baseline Proteinuria or eGFR: Post Hoc Analysis of the SANCTUARY Trial
Journal of the American Society of Nephrology·2025
Preservation of Humoral Immunity and Response to Vaccination and Infection in Felzartamab-Treated Patients with IgAN: Data from the Phase 2 IGNAZ Study
Journal of the American Society of Nephrology·2025
#2651 Sustainability and depth of UPCR reduction in patients with primary IgAN treated with nefecon: a secondary analysis of the Phase 3 NefIgArd trial
Nephrology Dialysis Transplantation·2025Open Access
#3251 Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NefIgArd study
Nephrology Dialysis Transplantation·2025Open Access
Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-On to Standard-of-Care Therapy in Individuals with Primary IgAN: Week 96 Data from an Open-Label Phase 1b Study
Journal of the American Society of Nephrology·2025
page 1 of 32Next →

Frequent Co-authors

John Feehally(21), Vladimı́r Tesař(16), Jürgen Floege(15), Rosanna Coppo(15), Brad H. Rovin(13), Daniel C. Cattran(10), Charles E. Alpers(10), Hong Zhang(10), Heather N. Reich(9), S. A. Roberts(9), Agnes B. Fogo(9), Hernán Trimarchi(9), Fernando C. Fervenza(8), Zhihong Liu(8), Sydney Tang(7), Jack F.M. Wetzels(7), H. Terence Cook(7), Alessandro Amore(7), Mark Haas(7), Antonello Pani(7)